YS 49

03/01/2011 - "The purpose of this study was to investigate the potential of CKD-712 as a medicine for sepsis and to confirm its protective effects on organs in animal sepsis models. "
11/01/2013 - "(S)-1-α-Naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD712) is noted as a drug candidate for sepsis. "
09/01/2011 - "CKD712, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, was considered as a new effective drug candidate to sepsis, based on its anti-inflammatory activity. "
03/01/2011 - "Taken together, these results show that CKD-712 has excellent potential as an effective medicine for sepsis."
03/01/2011 - "Pretreatment with CKD-712 dose-dependently increased survival rate in a lipopolysaccharide-induced sepsis model in mice. "

09/01/1999 - "YS 49 could therefore be beneficial in septic shock and other diseases associated with iNOS over-expression."
04/01/2017 - "CKD-712, a candidate treatment for septic shock, acts by increasing cardiac output. "
05/01/2002 - "These data strongly suggest that YS 51, a positional isomer of YS 49, might be beneficial in septic shock and/or endotoxin-induced inflammatory disorders."

12/01/2009 - "Thus CKD712 may be beneficial in the treatment of cardiovascular disorders such as atherosclerosis."
03/12/2008 - "Therefore, YS 49 has potential as a therapeutic strategy for the pathogenesis of Ang II-related vascular diseases such as hypertension and atherosclerosis, via the induction of HO-1 gene activity."

03/01/2011 - "Therapeutic efficacy of CKD-712 was also confirmed against sepsis following zymosan-induced endotoxemia and in cecal ligation and puncture surgery in mice. "

08/01/2009 - "Pretreatment with CKD712 significantly improved myocardial function as evidenced by an increase in the +/-dP/dt and a decrease in the infarct size, which were antagonized by a PI3K inhibitor, wortmannin (WT). "